Newave Pharmaceutical Inc
Clinical trials sponsored by Newave Pharmaceutical Inc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for tough blood cancers: LP-118 trial launches Results expected Dec 2026 (estimated)
-
New drug rocbrutinib takes on pirtobrutinib in blood cancer showdown
Disease control Recruiting nowThis study tests a new drug, rocbrutinib, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to treatment. All participants have already tried a type of BTK inh…
Phase 3 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for tough blood cancers: LP-118 trial launches
Disease control Recruiting nowThis early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…
Phase 1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill takes on tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental oral drug called LP-168 in about 60 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and to see how the drug behaves in the body…
Phase 1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC